Attached files

file filename
EX-99.2 - EX-99.2 - VERACYTE, INC.a16-20389_3ex99d2.htm
EX-99.1 - EX-99.1 - VERACYTE, INC.a16-20389_3ex99d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 1, 2016

 

VERACYTE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36156

 

20-5455398

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

6000 Shoreline Court, Suite 300, South San Francisco, California 94080

 

(Address of principal executive offices) (Zip Code)

 

 

Registrant’s telephone number, including area code: (650) 243-6300

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 8.01                                           Other Events.

 

On November 1, 2016, Veracyte, Inc. announced that it has commenced an underwritten public offering of its common stock. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

 

Veracyte, Inc. has updated its disclosures, including the addition of certain risk factors. The updated disclosures are filed herewith as Exhibit 99.2 and are incorporated herein by reference.

 

Item 9.01                                           Financial Statements and Exhibits.

 

(d)                                 Exhibits

 

99.1                        Press release issued by Veracyte, Inc. dated November 1, 2016.

 

99.2                        Disclosures.

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:  November 1, 2016

 

 

VERACYTE, INC.

 

 

 

 

 

By

/s/ Shelly D. Guyer

 

Name:

Shelly D. Guyer

 

Title:

Chief Financial Officer

 

 

(Principal Financial and Accounting Officer)

 

3



 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

99.1

 

Press release issued by Veracyte, Inc. dated November 1, 2016.

 

99.2

 

Disclosures.

 

 

4